Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Nomenclature of HBV core protein-targeting antivirals

Hepatitis B virus (HBV) core protein-targeting compounds are in or entering clinical development without a standardized nomenclature. We propose a naming convention for these core-targeting antiviral products to provide clarity and accelerate HBV drug development.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Mode of action of CAMs supporting the proposed nomenclature.


  1. Venkatakrishnan, B. & Zlotnick, A. The structural biology of hepatitis B virus: form and function. Annu. Rev. Virol. 3, 429–451 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Niklasch, M., Zimmermann, P. & Nassal, M. The hepatitis B virus nucleocapsid—dynamic compartment for infectious virus production and new antiviral target. Biomedicines 9, 1577 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  3. Luo, Y. et al. Identification of hepatitis B virus core protein residues critical for capsid assembly, pgRNA encapsidation and resistance to capsid assembly modulators. Antiviral Res. 191, 105080 (2021).

    Article  PubMed  Google Scholar 

  4. Schlicksup, C. J., Laughlin, P., Dunkelbarger, S., Wang, J. C.-Y. & Zlotnick, A. Local stabilization of subunit–subunit contacts causes global destabilization of hepatitis B virus capsids. ACS Chem. Biol. 15, 1708–1717 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Berke, J. M. et al. Antiviral properties and mechanism of action studies of the hepatitis B virus capsid assembly modulator JNJ-56136379. Antimicrob. Agents Chemother. 64, e02439-19 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Kim, H., Ko, C., Lee, J.-Y. & Kim, M. Current progress in the development of hepatitis B virus capsid assembly modulators: chemical structure, mode-of-action and efficacy. Molecules 26, 7420 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Mak, L.-Y., Seto, W.-K. & Yuen, M.-F. Novel antivirals in clinical development for chronic hepatitis B infection. Viruses 13, 1169 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  8. Janssen, H. et al. Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: interim week 24 data [abstract LBP12]. J. Hepatol. 73, S129–S130 (2020).

    Article  Google Scholar 

  9. Sulkowski, M. S. et al. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection. J. Hepatol. (2022).

    Article  PubMed  Google Scholar 

  10. Yuen, M.-F. et al. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection. J. Hepatol. (2022).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Fabien Zoulim.

Ethics declarations

Competing interests

F.Z. has received grants from Assembly Biosciences, Beam, Janssen and Viravaxx and is also a consultant for Assembly, Aligos, Antios, Arbutus, Gilead Sciences, GlaxoSmithKline, Janssen and Vir Biotechnology. A.Z. has equity in Assembly Biosciences and serves on their scientific advisory board. A.Z. is also a founder and Chief Scientific Officer of Door Pharmaceutical. J.F. is an employee of Aligos Therapeutics. A.G. is a former employee and current stakeholder of Gilead Sciences. J.H. has been supported by funding from the National Institute of Allergy and Infectious Disease/NIH and Gilead for work relevant here and has consulted for Arbutus, Bristol Myers Squibb, Gilead, Janssen, Roche and Sanofi. O.L. is an employee of Janssen and is a shareholder of Johnson & Johnson. N.M. is an employee of Arbutus Biopharma. W.D. is an employee at Assembly Biosciences and owns stock in Assembly Biosciences and Gilead. S.W. has received funding from Gilead. V.M. receives grant funding for the HBV Forum from Abbott, Aligos Therapeutis, Altimmune, Antios Therapeutics, Assembly Biosciences, Enanta Pharma, Enyo Pharma, Gilead, GlaxoSmithKline, Immunocore, Janssen, Monogram Biosciences, Quest Diagnostics, RFS Family Foundation, Roche, VenatorX, Vir Biotechnology and Virion. H.L.A.J. has received grants from AbbVie, Gilead, GlaxoSmithKline, Janssen, Roche and Vir Biotechnology, and is also a consultant for Aligos, Antios, Arbutus, Eiger, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Roche, VBI Vaccines, Vir Biotechnology and Viroclinics. S.B., E.D., M.K., K.L., M.N. and G.W. declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zoulim, F., Zlotnick, A., Buchholz, S. et al. Nomenclature of HBV core protein-targeting antivirals. Nat Rev Gastroenterol Hepatol 19, 748–750 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing